白蛋白结合型紫杉醇(Albumin-Bound Paclitaxel) - 药物靶点：Tubulin_在研适应症：转移性胰腺癌，胰腺癌，转移性胰腺腺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Nab-Paclitaxel、Nab-PTX、paclitaxel protein-bound

+ [14]

靶点

Tubulin

作用方式

抑制剂

作用机制

微管蛋白抑制剂

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [6]

在研适应症

转移性胰腺癌胰腺癌转移性胰腺腺癌+ [34]

非在研适应症

大肠腺癌小肠腺癌腺鳞癌+ [112]

原研机构

Abraxis BioScience, Inc.

在研机构

Hoffmann-La Roche, Inc.

American Regent, Inc.WhiteOak Pharmaceutical BV

+ [11]

非在研机构

Daiichi Sankyo Co., Ltd.

Pfizer Inc.Roche Pharma AG

+ [12]

权益机构

浙江海昶生物医药技术有限公司

BeOne Medicines Ltd.

科兴生物制药股份有限公司

+ [5]

最高研发阶段批准上市

首次获批日期

美国 (2005-01-07),

转移性乳腺癌

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS号33069-62-4

关联

1,677

项与白蛋白结合型紫杉醇相关的临床试验

NCT06592664

/ Withdrawn临床1/2期

A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
The main questions it aims to answer are:
* is the new drug plus standard treatment safe and tolerable
* is the new drug plus standard treatment more effective than standard treatment
Participants will:
* Visit the clinic three times every 28 days for treatment and tests
* Have CT or MRI scans every 8 weeks while on treatment

开始日期2030-01-01

申办/合作机构

Lisata Therapeutics, Inc.

NCT06998940

/ Not yet recruiting临床3期IIT

Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil [5-FU] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus standard chemotherapy alone in treating patients with KRAS wild type (WT) pancreatic ductal adenocarcinoma that cannot be removed by sugery (unresectable) or that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Panitumumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Chemotherapy drugs, such as nanoliposomal irinotecan, leucovorin, 5-FU, irinotecan, nab-paclitaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding panitumumab to standard chemotherapy may be effective in treating patients with unresectable, locally advanced, or metastatic KRAS WT pancreatic ductal adenocarcinoma.

开始日期2026-01-06

申办/合作机构

SWOG

[+1]

NCT07033689

/ Not yet recruiting早期临床1期

Open-label, Non-randomized, Single-center Study Investigating the Feasibility, Safety, Tolerability and Efficacy of Suizenji in Unresectable Pancreatic Ductal Adenocarcinoma Patients

This is a feasibility, safety, tolerability, and efficacy research study of an investigational device called "Suizenji", an ultrasound-guided high-intensity focused ultrasound (HIFU) therapy system for the treatment of unresectable pancreatic ductal adenocarcinoma. Focused ultrasound therapy uses a number of small ultrasound generators attached to a bowl-shaped ultrasound generator to emit ultrasound waves from outside to inside the body and focus them on a single point where cancerous cells in the pancreas are located. The targeted area is then heated, which kills the pancreatic cancer cells, and as a result, the patient's life may be prolonged. Experience with Suizenji for pancreatic cancer patients has shown that the "heating" is only a warm feeling in the abdomen during the treatment.

开始日期2025-12-01

申办/合作机构

Sonire Therapeutics Inc

100 项与白蛋白结合型紫杉醇相关的临床结果

登录后查看更多信息

100 项与白蛋白结合型紫杉醇相关的转化医学

登录后查看更多信息

100 项与白蛋白结合型紫杉醇相关的专利（医药）

登录后查看更多信息

43,053

项与白蛋白结合型紫杉醇相关的文献（医药）

2025-12-31·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies

Article

作者: Bartuzi, Damian ; Stepulak, Andrzej ; Kalafut, Joanna ; Okon, Estera ; Wawruszak, Anna ; Czerwonka, Arkadiusz ; Luszczki, Jarogniew

Sirtuins (SIRTs) are NAD+-dependent histone deacetylases, which play a key role in cancer progression; however, their prognostic values in breast cancer (BC) remain a subject of debate and controversy. Accumulative evidence suggests that each sirtuin possesses individual character, implicating its role in the regulation of multifaceted biological functions leading to BC initiation, progression and metastasis. Selisistat (EX527) is a potent, cell permeable, highly selective SIRT1 inhibitor. In the study, the tumour-suppressive effects of the SIRT1 inhibitor EX527 (selisistat) alone and in combination with paclitaxel (PAX) in different breast cancer cell lines and zebrafish xenograft models were investigated. The type of pharmacological drug-drug interaction between EX527 and PAX was determined using the isobolographic method. EX527 and PAX used individually inhibited proliferation, induced apoptosis and caused cell cycle arrest in G1 and subG1/G2 phases. Interestingly, the combination of these compounds used in the 1:1 dose-ratio augmented all these effects (IC_50add 29.52 ± 3.29 - 38.45 ± 5.26). The co-treatment of EX527 with PAX generated desirable additive drug-drug interaction. The simultaneous application of EX527 and PAX induced a stronger inhibition of tumour growth compared to individual treatments in zebrafish xenografts. In silico analysis revealed a protein-protein interaction pathway (SIRT1-AKT-S1PR1-GNAI1/GNAO1-Tubulin) connecting molecular targets of both ligands. To summarise, the combination of EX527 and PAX more effectively impairs breast cancer cell growth compared to individual treatments. However, further investigations are required to clarify the specific targets and molecular mechanisms underlying the activity of EX527:PAX in other preclinical models.

2025-12-01·Journal of Gastrointestinal Cancer

The Efficacy and Safety of Nivolumab Combined with Nab-Paclitaxel or Oxaliplatin as a First-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

Article

作者: Li, Shuman ; Ye, Sisi ; Li, Juan ; Zhang, Ying ; Liu, Rongrui ; Shi, Weiwei

OBJECTIVE:

This study aims to assess the therapeutic efficacy and safety of nivolumab combined with chemotherapy as a first-line treatment for advanced or metastatic gastric cancer, specifically comparing the outcomes of oxaliplatin-based versus albumin-bound paclitaxel (nab-paclitaxel)-based therapies.

METHODS:

We retrospectively analyzed 93 patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma treated at the First Medical Center of Chinese PLA General Hospital from September 2017 to November 2022. Patients were categorized into the nivolumab + oxaliplatin (N-OX group) or nivolumab + nab-paclitaxel (N-AP group) based on the chemotherapy regimen. Progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety were evaluated as endpoints.

RESULTS:

At the end of the follow-up period on September 31, 2023, we reported an ORR of 65.6% and DCR of 95.7% across all patients. The median PFS was 8.4 months, with no significant difference between the N-OX and N-AP groups (median, 7.8 vs 9.5 months; P = 0.450). Notably, patients with diffuse gastric cancer in N-AP group showed a 44.7% reduction in tumor progression risk compared with the N-OX group (P = 0.046). The overall safety profile was acceptable in two groups.

CONCLUSIONS:

Our study suggested that nivolumab combined with chemotherapy was effective and safe as a first-line intervention for advanced gastric cancer. While both oxaliplatin and nab-paclitaxel regimens showed similar efficacy, the nab-paclitaxel may offer additional benefits for patients with diffuse gastric cancer. Further research is encouraged to confirm these findings and refine treatment strategies.

2025-12-01·MOLECULAR BIOLOGY REPORTS

Human papillomavirus E6 alters Toll-like receptor 9 transcripts and chemotherapy responses in breast cancer cells in vitro

Article

作者: Selander, Katri ; Jukkola, Arja ; Ravaioli, Sara ; Parviainen, Essi ; Manninen, Aki ; Nurmenniemi, Sini ; Bravaccini, Sara

Abstract:

Background:

Toll-like receptor 9 (TLR9) is a DNA recognizing receptor expressed also in several cancers. Decreased TLR9 expression is associated with poor prognosis in triple negative breast cancer (TNBC), but the role of TLR9 in breast cancer pathophysiology is currently unclear. Regulation of TLR9 expression in breast cancer is poorly understood. Human papillomavirus (HPV) infections suppress TLR9 expression in cervical cancers but the association between HPV and breast cancer has remained controversial. The aim of this study was to test if HPV16 can suppress TLR9 expression in breast cancer cells and affect cell behavior.

Methods and results:

Human T-47D and MDA-MB-231 breast cancer cells were transduced with lentivirus encoding HPV16 E6 oncoprotein. The effects of E6 on TLR9 mRNA and protein expression, and cell proliferation, migration, invasion and sensitivity to chemotherapy were studied in vitro. Breast cancer tissue samples (n = 37) were analyzed for the presence of HPV DNA. E6 expression decreased TLR9 mRNA expression in MDA-MB-231 and T-47D cells in hypoxia. E6 expression altered breast cancer cell proliferation and made cells significantly less sensitive to the growth inhibitory effects of chemotherapeutic agents. HPV L1 gene was not detected in a small pilot cohort of clinical breast cancer specimens.

Conclusion:

HPV16 may influence breast cancer cell TLR9 transcription and chemotherapy responses and could thereby affect breast cancer prognosis. These results suggest that HPV may have a previously unrecognized role in breast cancer pathophysiology and warrant further studies on the topic.

1,431

项与白蛋白结合型紫杉醇相关的新闻（医药）

10 小时之前

·今日头条

绝境逢生！铂耐药卵巢癌新药获美国FDA批准，12个月生存率达60%

卵巢癌是导致女性癌症死亡的第五大常见原因。接受含铂疗法后六个月内复发的患者被定义为“铂耐药”卵巢癌，这类患者治疗选择有限，复发后单药化疗的中位总生存期仅约12个月。 2025年7月14日，抗癌领域传来振奋消息：美国FDA受理了针对铂耐药性卵巢癌药物——relacorilant的新药申请（NDA），该药此前已获FDA孤儿药资格认定。这一进展为长期面临治疗困境的铂耐药卵巢癌患者点亮了新希望，为患者带来延长生存期、改善生活质量的精准治疗新选择！ ▲截图源自“OncLive” Relacorilant联合疗法将铂耐药卵巢癌生存期延长近5个月，12个月OS率达60% Relacorilant是Corcept公司研发的一款口服选择性糖皮质激素受体（GR）拮抗剂（SGRA），通过特异性结合GR调节皮质醇活性（不作用于其他激素受体），可增强肿瘤对化疗诱导细胞凋亡的敏感性，目前正开发用于卵巢癌、前列腺癌等治疗。该药的新药申请（NDA）获关键性3期ROSELLA试验（NCT05257408）积极数据支持。该研究纳入381例既往接受过紫杉烷类和贝伐单抗治疗（其中61%曾接受PARP抑制剂治疗）的女性患者，随机分为两组：联合治疗组（relacorilant+白蛋白结合型紫杉醇，n=188）、白蛋白结合型紫杉醇单药组（n=193）。结果显示：联合治疗组疗效显著优于单药组：中位无进展生存期（PFS）延长至6.54个月（95%CI,5.55-7.43），而单药组PFS仅为5.52个月（95%CI,3.94-5.88）（HR=0.70，P=0.0076），且 PFS率也更高，6个月PFS率分别为52%（联合治疗组）vs 42%（单药治疗组），12个月PFS率分别为25%（联合治疗组）vs 13%（单药治疗组）。 ▲图源“JCO”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除中期分析显示，联合治疗组中位总生存期（OS）显著延长至16.0个月，单药组仅为11.5个月，HR=0.69，95%CI:0.52-0.92，P=0.01）， 12个月OS率达60%，单药组仅为49% 。此外，联合治疗组客观缓解率（ORR）在数值上更高（36.9% vs 30.1%），且未增加额外安全风险。小编寄语近年来，卵巢癌的治疗已经取得了长足的进展，逆转了晚期患者的生存期，除了上面整理的内容，还有更多的新药正在研发中。如果您想了解卵巢癌更多抗癌新药/新技术的更多讯息，可将治疗经历、近期病理检查报告、出院小结等，提交至全球肿瘤医生网医学部，进行初步评估。参考资料 [1]Olawaiye A,et al. ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72)[J]. 2025. https://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA5507 [2]https://www.onclive.com/view/fda-receives-nda-for-relacorilant-in-platinum-resistant-ovarian-cancer 本文为全球肿瘤医生网原创，未经授权严禁转载

孤儿药临床结果临床3期

10 小时之前

·今日头条

WT1-DC疫苗联合化疗逆转癌王耐药困局，胰腺癌中位总生存超3年

胰腺导管腺癌（PDAC）是一种死亡率极高的恶性肿瘤，其显著特征是对细胞毒性化疗和放射疗法存在固有耐药性。这一特性导致无法切除的胰腺导管腺癌（UR-PDAC）患者临床治疗效果不佳，因此，研发既针对肿瘤细胞、又能靶向肿瘤微环境（TME）的新型疗法，成为改善患者预后的迫切需求。近日，《免疫肿瘤学杂志》报道了一项突破性研究：应用多功能 WT1-DC 疫苗治疗不可切除晚期胰腺导管腺癌（UR-PDAC）的 Ⅰ 期临床试验，公布了令人振奋的初步数据 —— 所有入组患者中位OS超3年、PFS超2年！WT1-DTH 长期阳性患者生存期更是达4.5 年！这一突破为长期困于治疗绝境的晚期胰腺癌患者点亮了跨越数年的生存希望，让难治性胰腺癌的治疗迎来了值得期待的新曙光！ ▲截图源自“PMC” WT1-DC疫苗联合化疗让晚期患者肿瘤负荷大降，生存期达3.52年，中位无进展生存期达2.23年 WT1是一种与血管生成、肿瘤进展、侵袭及转移密切相关的转录因子，在肿瘤发生中发挥致癌作用。它不仅表达于胰腺导管腺癌（PDAC）细胞，还存在于肿瘤微环境（TME）的癌症干细胞、髓系抑制细胞（MDSC）及肿瘤血管中，这使其成为极具潜力的癌症治疗靶点。而树突状细胞（DC）作为专业抗原呈递细胞，在启动和调节肿瘤相关抗原特异性免疫反应中起着关键作用。基于此，研究团队开发出一种新型WT1肽脉冲树突状细胞（WT1-DC）疫苗，Ⅰ期临床研究数据同步发表于《免疫肿瘤学杂志》中。该研究共纳入10例不可切除晚期胰腺导管腺癌（UR-PDAC）患者，包括6例局部晚期胰腺导管腺癌（LA-PDAC）、3例转移性胰腺导管腺癌（M-PDAC）、1例术后复发患者，均经病理确诊为腺癌，且表达WT1和MHCⅠ类分子。入组后，先接受白蛋白结合型紫杉醇+吉西他滨联合化疗，再接受WT1-DC疫苗治疗。结果显示：在9例可评估预后的患者中，WT1肽特异性迟发型超敏反应（WT1-DTH）长期阳性患者（n=4）的临床疗效显著优于短期阳性患者（n=5），且所有WT1-DTH长期阳性患者的生存期均达到至少4.5年。此外，所有患者的肿瘤负荷均有下降（降幅0.0%-57.4%）（详见下图）。 ▲图源“J Immunother Cancer”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除其中 7例患者（6例局部晚期胰腺导管腺癌、1例转移性胰腺导管腺癌）实现部分缓解（PR），其余 3例维持长期疾病稳定（SD）。治疗约6个月后，患者肿瘤最大标准摄取值（SUVmax）显著下降（p=0.006）。下图展示了4例不可切除晚期胰腺导管腺癌（UR-PDAC）患者（编号WT1-DC-01、WT1-DC-03、WT1-DC-05、WT1-DC-09），在接受治疗前后的CE-CT与¹⁸F-FDGPET/CT影像对比，清晰展示了治疗带来的变化。 ▲图源“J Immunother Cancer”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除此外，生存数据更为亮眼： 9例患者的中位无进展生存期（PFS）达2.23年，中位总生存期（OS）达3.52年（详见下图A）。其中， 5例局部晚期胰腺导管腺癌（LA-PDAC）患者的中位PFS为2.48年，总生存期尚未达到；而 3例转移性胰腺导管腺癌（M-PDAC）患者的中位PFS达1.37年、中位OS达2.41年（详见下图B）。 ▲图源“J Immunother Cancer”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除综上，通过WT1-DC疫苗联合化疗的免疫治疗方案，可强效激活UR-PDAC患者的WT1特异性免疫反应，有望调节肿瘤微环境并为部分患者争取转化手术机会，最终带来显著的临床获益。小编寄语树突状细胞（DC）作为体内唯一能激活初始T细胞的抗原提呈细胞，在免疫反应中占据核心地位。目前，DC疫苗虽多数仍处于早期临床试验阶段，但已在部分国家正式应用于临床。对于早期肿瘤患者，术后采用DC疫苗联合放化疗的辅助治疗方案，可通过清除残留癌细胞、形成免疫记忆，降低复发转移风险。目前，树突状疫苗在日本、德国等，用于临床辅助治疗多种癌症，包括皮肤癌、肝癌、肺癌、肾癌、乳腺癌等。想了解树突状细胞疫苗等抗癌新技术更多讯息的患者，可将近期病理报告、影像学检查资料、治疗经历等，提交至全球肿瘤医生网医学部，进行初步评估或了解详细的入排标准。参考资料 [1]Koido S,et al.Dendritic cells pulsed with multifunctional Wilms' tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer. J Immunother Cancer. 2024 Oct 8;12(10):e009765. https://pmc.ncbi.nlm.nih.gov/articles/PMC11474828/ 本文为全球肿瘤医生网原创，未经授权严禁转载

临床结果疫苗放射疗法临床2期临床3期

12 小时之前

·PipelineReview

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, CA, USA I July 14, 2025 I Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary, selective cortisol modulator, relacorilant, to treat patients with platinum-resistant ovarian cancer. Corcept’s filing is based on positive data from its pivotal Phase 3 ROSELLA and Phase 2 trials. In these trials, patients who received relacorilant plus nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel monotherapy, with no need for biomarker selection. Relacorilant was well-tolerated, consistent with its known safety profile. Importantly, the type, frequency and severity of adverse events in the combination arms were similar to those in the nab-paclitaxel monotherapy arms. Relacorilant did not increase the safety burden of the patients who received it. “This submission is an important milestone for Corcept as we now have two New Drug Applications before the FDA: Relacorilant in combination with nab-paclitaxel as a treatment for people with platinum-resistant ovarian cancer and relacorilant as a treatment for patients with hypercortisolism,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. “Better treatment options are needed for the many patients living with these diseases. Our oncology and endocrinology business units are already working to make sure relacorilant is available immediately following regulatory approval.” About Relacorilant Relacorilant, an oral therapy, is a selective glucocorticoid receptor (GR) antagonist that modulates cortisol activity by binding to the GR but not to the body’s other hormone receptors. Corcept is developing relacorilant in ovarian cancer and a variety of other serious disorders, including endogenous hypercortisolism and prostate cancer. Relacorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. It has been designated an orphan drug by the FDA and the European Commission (EC) for the treatment of hypercortisolism and by the EC for the treatment of ovarian cancer. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025 for relacorilant as a treatment for patients with hypercortisolism. About Cortisol’s Role in Oncology Cortisol plays a role in tumor growth through several mechanisms. It helps solid tumors resist chemotherapy by inhibiting cellular apoptosis — the tumor-killing effect chemotherapy is meant to stimulate. In some cancers, cortisol promotes tumor growth by activating oncogenes in the cells to which it binds. Cortisol also suppresses the body’s immune response, which weakens its ability to fight all diseases, including cancer. About Platinum-Resistant Ovarian Cancer Ovarian cancer is the fifth most common cause of cancer death in women. Patients whose disease returns less than six months after receiving platinum-containing therapy have “platinum-resistant” disease. There are few treatment options for these women. Median overall survival following recurrence is approximately 12 months with single-agent chemotherapy. Approximately 20,000 women with platinum-resistant disease are candidates to start a new therapy each year in the United States, with at least an equal number in Europe. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders, leading to the discovery of more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com . SOURCE: Corcept Therapeutics

临床结果孤儿药申请上市临床3期上市批准

100 项与白蛋白结合型紫杉醇相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
转移性胰腺癌	秘鲁	浙江海昶生物医药技术有限公司	2025-05-14
胰腺癌	中国	Bristol Myers Squibb Co.	2024-01-05
转移性胰腺腺癌	美国	Teva Pharmaceuticals, Inc.	2023-05-11
不能切除性胰腺癌	日本	Taiho Pharmaceutical Co., Ltd.	2014-12-18
胃癌	日本	Taiho Pharmaceutical Co., Ltd.	2013-02-21
乳腺癌	中国	Abraxis BioScience, Inc.	2008-06-30
非小细胞肺癌	欧盟	Bristol-Myers Squibb Pharma EEIG	2008-01-11
非小细胞肺癌	冰岛	Bristol-Myers Squibb Pharma EEIG	2008-01-11
非小细胞肺癌	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2008-01-11
非小细胞肺癌	挪威	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	欧盟	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	冰岛	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	挪威	Bristol-Myers Squibb Pharma EEIG	2008-01-11
转移性乳腺癌	美国	Bristol Myers Squibb Co.	2005-01-07

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期乳腺癌	临床3期	中国	石药集团欧意药业有限公司	2023-04-27
进展期胃腺癌	临床3期	中国	石药集团欧意药业有限公司	2020-03-01
PD-L1阳性三阴性乳腺癌	临床3期	阿根廷	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	智利	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	捷克	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	法国	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	匈牙利	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	意大利	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	墨西哥	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	秘鲁	Hoffmann-La Roche, Inc.	2019-12-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03377491 (PANOVA-3, ASCO2025) 人工标引	临床3期	晚期胰腺导管腺癌	571	TTFields + gemcitabine/nab-paclitaxel (GnP)	繭製憲襯築窪蓋膚顧餘(簾襯淵鬱簾鑰網艱窪鹽) = 顧蓋構蓋繭構糧願衊願繭鬱築願襯鏇艱蓋齋願 (遞網範蓋構構艱選鹹糧, 15.0 ~ 18.0) 更多	积极	2025-06-04
				Gemcitabine/nab-paclitaxel (GnP)	繭製憲襯築窪蓋膚顧餘(簾襯淵鬱簾鑰網艱窪鹽) = 構窪簾艱網夢襯艱壓齋繭鬱築願襯鏇艱蓋齋願 (遞網範蓋構構艱選鹹糧, 12.8 ~ 15.4) 更多
NCT04390958 (Pubmed \| Int J Surg)	临床2期	局部晚期食管鳞状细胞癌新辅助	-	Albumin-bound paclitaxel plus cisplatin and capecitabine (APC regimen)	遞鹹齋膚窪顧鏇顧蓋鏇(願製選製鹽選築醖鑰廠) = 衊鏇選鹹願簾鏇憲膚蓋鏇鏇蓋顧網鏇糧膚鏇餘 (餘構簾顧鬱窪範膚糧廠, 18.8% ~ 38.6) 更多	积极	2025-06-01
				Placebo	繭繭鏇壓醖艱鏇選築壓(夢醖齋顧夢願齋鹹製製) = 齋鏇鏇淵選願餘淵遞醖範積憲鑰積鑰選觸網積 (鬱築夢鬱醖鑰淵顧夢糧 ) 更多
NCT03678883 (1801 part 3B, ASCO2025)	临床2期	转移性胰腺导管腺癌 CA 19-9 levels \| IFNβ \| PD-L1	-	Elraglusib 9.3 mg/kg IV once weekly + Gemcitabine/nab-paclitaxel	鏇觸齋壓醖簾壓構齋製(簾選簾繭遞糧積憲築壓) = 鹹築積觸範糧壓鹽窪襯鏇膚窪糧選窪憲衊遞繭 (膚積齋膚蓋鹽簾憲構構 ) 更多	积极	2025-05-30
				Gemcitabine/nab-paclitaxel	鏇觸齋壓醖簾壓構齋製(簾選簾繭遞糧積憲築壓) = 鏇製遞築鑰鑰願築構製鏇膚窪糧選窪憲衊遞繭 (膚積齋膚蓋鹽簾憲構構 ) 更多
NCT04247165 (LAPTOP, ASCO2025)	临床1/2期	转移性胰腺癌	55	Nivolumab	壓觸獵夢壓艱製糧窪蓋(蓋積壓壓遞淵餘顧夢選) = 鑰顧艱齋築壓獵簾蓋積醖膚鏇鑰觸餘夢衊製觸 (築簾積築鏇鑰選顧襯憲, 53.3 ~ 90.2) 更多	积极	2025-05-30
				Ipilimumab	壓觸獵夢壓艱製糧窪蓋(蓋積壓壓遞淵餘顧夢選) = 構範網膚餘願網夢壓齋醖膚鏇鑰觸餘夢衊製觸 (築簾積築鏇鑰選顧襯憲, 42.2 ~ 78.2) 更多
NCT05669482 (RAMP 205, ASCO2025)	临床1/2期	转移性胰腺导管腺癌一线 activating KRAS mutations	54	Avutometinib/Defactinib + Gemcitabine/nab-paclitaxel	構網窪餘鏇構觸糧製築(築衊齋蓋夢構鏇膚鏇壓) = 41% 齋鹹衊膚鑰鏇簾糧願壓 (網願糧鏇觸廠簾獵齋鑰 ) 更多	积极	2025-05-30
ASCO2025	N/A	晚期胆道癌二线	84	Nab-paclitaxel-based chemotherapy + ICI	製範繭鹹觸積願艱鏇鹽(餘廠艱遞壓觸獵夢獵觸) = 膚鑰鬱鹹糧壓襯築製蓋齋窪鬱餘鬱糧艱鬱製淵 (鹽膚艱膚繭糧艱觸簾鑰 ) 更多	积极	2025-05-30
				Nab-paclitaxel-based chemotherapy	製範繭鹹觸積願艱鏇鹽(餘廠艱遞壓觸獵夢獵觸) = 築願構願繭構壓獵顧觸齋窪鬱餘鬱糧艱鬱製淵 (鹽膚艱膚繭糧艱觸簾鑰 ) 更多
ASCO2025	临床1/2期	晚期胰腺腺癌	-	Gemcitabine/nab-paclitaxel (GN)	鬱夢製鬱憲製齋餘壓鏇(選鹽願積憲遞繭鹽鏇襯): HR = 5.2 (95% CI, 0.63 ~ 0.92), P-Value = 0.01	积极	2025-05-30
				GN/cisplatin (GCN)
NCT05218889 (NCT05218889, ASCO2025)	临床1/2期	转移性胰腺导管腺癌一线 M1/M2 macrophage percentages	96	NASCA regimen (Surufatinib, Camrelizumab, Nab-Paclitaxel, S-1)	顧壓鏇膚醖廠餘遞醖製(壓膚鏇網繭顧糧鹽願鬱) = 鹹鹹艱餘積壓製繭壓衊選鏇蓋積構淵積糧獵鏇 (顧鏇鬱鹹窪選構觸簾衊 ) 更多	积极	2025-05-30
				AG regimen (Nab-Paclitaxel, Gemcitabine)	顧壓鏇膚醖廠餘遞醖製(壓膚鏇網繭顧糧鹽願鬱) = 獵網顧鹽範築艱夢願壓選鏇蓋積構淵積糧獵鏇 (顧鏇鬱鹹窪選構觸簾衊 ) 更多
NCT02767557 (Pubmed \| J Clin Oncol)	临床2期	胰腺癌一线 growth differentiation factor 15 (GDF15)	147	Gemcitabine/nab-paclitaxel with Tocilizumab	鹹衊遞齋繭積網範鑰鬱(淵築網構艱齋憲淵衊膚) = 選衊夢夢範窪網憲鬱鹹壓遞範獵構壓築網憲糧 (鹹壓鹽蓋齋醖憲窪範鹽, 56.3 ~ 78.1) 更多	积极	2025-05-12
				Gemcitabine/nab-paclitaxel without Tocilizumab	鹹衊遞齋繭積網範鑰鬱(淵築網構艱齋憲淵衊膚) = 積蓋襯糧淵壓積觸醖蓋壓遞範獵構壓築網憲糧 (鹹壓鹽蓋齋醖憲窪範鹽, 49.6 ~ 72.1) 更多
NCT05673811 (VIRAGE, GlobeNewswire) 人工标引	临床2期	转移性胰腺癌一线	96	VCN-01 + Gemcitabine/nab-paclitaxel	鏇襯鏇築襯網觸鬱獵憲(觸製簾觸遞齋顧鏇餘蓋) = 範願簾廠顧鹹膚繭顧獵夢憲構願範窪憲襯簾蓋 (鹹獵蓋糧簾廠範範顧簾 ) 达到更多	积极	2025-05-07
				Gemcitabine/nab-paclitaxel	鏇襯鏇築襯網觸鬱獵憲(觸製簾觸遞齋顧鏇餘蓋) = 壓壓壓積廠顧衊顧鹽顧夢憲構願範窪憲襯簾蓋 (鹹獵蓋糧簾廠範範顧簾 ) 达到更多